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Abstract
Background: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children
against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have
studied the effect of a booster or delayed primary dose of 7-valent conjugate vaccine (PCV-7) on antibody and
nasopharyngeal carriage of pneumococci 3–4 years after primary vaccination.
Methodology/Principal Findings: We recruited a subsample of children who had received 3 doses of either PCV-9 or
placebo (controls) into this follow-up study. Pre- and post- PCV-7 pneumococcal antibody concentrations to the 9 serotypes
in PCV-9 and nasopharyngeal carriage of pneumococci were determined before and at intervals up to 18 months post-PCV-
7. We enrolled 282 children at a median age of 45 months (range, 38–52 months); 138 had received 3 doses of PCV-9 in
infancy and 144 were controls. Before receiving PCV-7, a high proportion of children had antibody concentrations
.0.35 mg/mL to most of the serotypes in PCV-9 (average of 75% in the PCV-9 and 66% in the control group respectively).
The geometric mean antibody concentrations in the vaccinated group were significantly higher compared to controls for
serotypes 6B, 14, and 23F. Antibody concentrations were significantly increased to serotypes in the PCV-7 vaccine both 6–8
weeks and 16–18 months after PCV-7. Antibodies to serotypes 6B, 9V and 23F were higher in the PCV-9 group than in the
control group 6–8 weeks after PCV-7, but only the 6B difference was sustained at 16–18 months. There was no significant
difference in nasopharyngeal carriage between the two groups.
Conclusions/Significance: Pneumococcal antibody concentrations in Gambian children were high 34–48 months after a 3-
dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher
than in control children for 3 of the 9 serotypes. Antibody concentrations increased after PCV-7 and remained raised for at
least 18 months.
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Introduction
Streptococcus pneumoniae (the pneumococcus) is estimated to cause
nearly one million childhood deaths each year [1]. Most of these
deaths occur in developing countries where the pneumococcus is
the most frequent cause of childhood pneumonia and where
mortality from pneumococcal meningitis is high (around 50%)
with many survivors left with severe neurologic disabilities [2,3].
There is a high burden of pneumococcal disease in The Gambia
[4,5] where the pneumococcus is the most prevalent bacterial
pathogen isolated from children with pneumonia and is respon-
sible for about 50% of cases of pyogenic meningitis [3,4,6]. About
40% of the serogroups responsible for invasive disease in young
children in The Gambia are covered by the 7-valent pneumococ-
cal conjugate vaccine (PrevenarR, Pfizer) and about 80% by the 9-
valent pneumococcal conjugate vaccine used in trials in The
Gambia and South Africa [4,5,7,8].
Pneumococcal conjugate vaccines prevent invasive pneumococ-
cal diseases (IPD) both directly and indirectly by reducing
transmission [9,10]. The 9-valent pneumococcal conjugate
vaccine (PCV-9) given in a 3-dose schedule beginning at 6 weeks
of age, with a minimum of 4-week intervals between doses,
induced protective levels of anti-pneumococcal antibodies [11]
and provided protection against IPD, pneumonia and all-cause
mortality in Gambian children up to the end of follow-up at age 30
months [12]. Antibody concentrations with conjugate vaccines
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decline after primary vaccination. The rate of decline and the
persistence of immunologic memory are important parameters in
determining the potential need and time for booster vaccination
[13]. Gambian children who received primary vaccination with 2
or 3 doses of a 5-valent PCV in infancy showed immunologic
memory at 24 months of age [14], but there are few data on
declines in antibody concentration or on the persistence of
immunologic memory beyond this period in children in develop-
ing countries.
The currently recommended regimen for PCV in the United
States is to follow primary immunization at 2, 4 and 6 months of
age with a booster dose in the second year of life [15]. The high
prevalence of nasopharyngeal carriage in developing countries
such as The Gambia could provide natural boosting such that the
kinetics of the antibody response to PCV could differ from that
seen in developed countries and make a booster dose unnecessary,
with important cost savings for countries with limited resources.
To inform international policy on whether there is a need for
booster immunization in low-income countries, more information
is needed on the longevity of the antibody response following
primary immunization in settings where pneumococcal carriage
and diseases are common. We have, therefore, investigated the
persistence of pneumococcal antibodies more than 3 years after
primary vaccination in early infancy in children who had
previously participated in the Gambian Pneumococcal Vaccine
Trial (PVT) [12].
Methods
Setting and recruitment of study participants
The subjects who participated in this study had previously taken
part in a double blind, placebo-controlled, individually random-
ized trial of PCV-9 that took place in The Gambia between 2000
and 2004 [12]. This trial enrolled 17,437 children, who received
three doses of either PCV-9 (vaccinated group) or placebo (control
group). The primary immunization schedule adopted for this trial
was vaccination at 6, 10 and 14 weeks of age but due to the rural
setting, the median age at receipt of the first dose of vaccine or
placebo was 11 weeks (inter quartile range [IQR] 8–16 weeks) and
for the third dose it was 24 weeks (IQR 19–32 weeks) [12]. After
the trial results were reviewed, Wyeth vaccines kindly donated 7-
valent PCV vaccine (PCV-7) for all children in the study area in
the age cohort that would have been eligible to participate in the
trial. A week- long vaccination campaign with PCV-7 was
organized by the Gambian Ministry of Health in Upper and
Central River Regions in June 2005 for all children aged 2–4
years, and approximately 27,000 children (an estimated 87% of
the eligible total) were vaccinated with one dose, which served as
booster dose for children who had previously received PCV-9 and
as delayed primary immunization for the control group. A subset
of participants from the vaccinated group was selected for the
current evaluation of antibody persistence and response to booster
vaccination with PCV-7, and the impact of delayed primary
immunization with PCV-7 was studied in a subset of children in
the previous control group. Nasopharyngeal carriage of pneumo-
cocci was studied in both groups.
A list was generated of subjects aged 3–4 years who had
received three doses of PCV-9 or placebo during the PCV-9 trial
and who lived near to one of a selected number of health centres to
allow for ease of follow up. Children for participation in the follow-
up study were recruited sequentially from this list until the
required sample size had been reached. The study participants
were not age or sex matched. Separate consent for participation of
children selected for this extended study was obtained from
parents/guardians of the participants before enrollment. The field,
clinical and laboratory investigators were blind to the group of the
study participants. The study was approved by the Joint Gambian
Government/MRC Ethics Committee.
Enrolment, follow up and sampling
At enrolment into the follow-up study in late May 2005, a 3 ml
venous blood sample and a nasopharyngeal swab were collected.
The calcium alginate fibre tip of the applicator swab was cut off,
placed in a container of skim milk-tryptone-glucose-glycerin
(STGG) transport medium, and held frozen at 270uC until
analyzed. Serum was separated and kept frozen at 220uC until
analysis. A full dose of PCV-7 (Pfizer) was given during the
campaign from 8–15 June 2005. Study participants were seen at
6–8 weeks, 5 months and 16–18 months following booster/
delayed primary PCV-7 vaccination when further samples were
taken for determination of antibody concentrations (at 6–8 weeks
and 16–18 months) and carriage of pneumococci (all visits)
(Figure 1).
Laboratory methods
Serology: Concentrations of serotype-specific anti-pneumococ-
cal polysaccharide IgG antibodies were measured by enzyme
linked immunoassay (ELISA). Test samples and controls were
tested for type-specific IgG antibodies to the nine-polysaccharides
in PCV-9 (1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F) according to an
adapted WHO protocol as described previously [11].
Microbiology: Vials containing a tip of a nasopharyngeal swab
(NPS) in transport medium were thawed to room temperature
and 100 ml of the sample were diluted ten-fold with sterile
Tryptone Soya Broth (TSB). 100 ml of broth were plated onto a
selective gentamicin blood agar plate, which was incubated for
18–24 hours at 35uC in an atmosphere containing 5% carbon
dioxide. Aliquots of isolates in 15% glycerol broth were kept
frozen at 270uC for future analysis. Identification of pneumo-
cocci was based on cultural morphology, susceptibility to
ethylhydrocupreine hydrochloride (optochin) and sodium deoxy-
cholate (bile solubility). Serotyping was performed with capsular
and factor-typing sera (Statens Serum Institut, Copenhagen,
Denmark), using a latex agglutination assay as described pre-
viously [16]. Isolates with equivocal results were confirmed by the
Quellung reaction. S. pneumoniae (ATCC 49619) was used as a
quality control strain. All laboratory assays were done blinded to
the child’s study group.
Statistical analyses
To give a study with 90% power (alpha 0.05) to detect a 30%
reduction in carriage of pneumococci of vaccine serotype in infants
who had received PCV-9 in infancy at the time of booster
immunization, assuming an NP carriage rate of pneumococci of
vaccine serotype of 75% based on earlier small studies in non-
vaccinated children [14,17] a sample size of 110 children per
group was needed. This was increased to allow for losses to follow-
up. Differences in antibody concentrations between the groups
were determined by comparing the geometric means, as well as
the proportions of children with an antibody concentration of
$0.35 mg/mL, the concentration considered to be protective
against IPD [18]. Geometric means of the antibody concentrations
in the two groups were compared by the two-sample t-test. For
categorical variables, groups were compared using the Chi-
Squared test, or for small numbers, Fisher’s exact test. The
Holm’s method was used to adjust the P-values for multiple
comparisons between groups [19].
Antibody Level and Carriage after PCV Immunization
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Results
We recruited 284 participants and obtained adequate blood
samples from 282, including 138 previously vaccinated with PCV-
9 and 144 controls. The mean age at first visit for the follow-up
study was 45 months. Age, gender and area of domicile were
similar between the two study groups (data not shown). At the final
visit 16–18 months after PCV-7, 113 (82%) and 116 (81%)
children from vaccinated and control groups respectively were
evaluated. There was no significant difference in the number of
children who dropped out of the study between the groups, neither
was there any difference in the reasons for failure to participate
further in the study (Figure 1). The period that had elapsed
between the last dose of PCV-9 or placebo and receipt of PCV-7
ranged from 34 to 48 months.
Anti-pneumococcal antibody concentrations before PCV-
7 vaccination
The baseline antibody concentrations before booster/delayed
primary vaccination with PCV-7 were high for most of the PCV-9
serotypes, although lower than those reported 4-weeks after
administration of the third dose of PCV-9 in the original trial [11]
(Table 1). The average (range) of the proportions of children who
had protective antibody concentrations ($0.35 mg/mL) for each
serotype at baseline was 75.0% (47.4–99.3%) and 65.9% (36.8–
96.5%) for the vaccinated and control children respectively
(Table 2). There was considerable variation in the mean antibody
concentration seen for individual polysaccharides (Table 1, Fig. 2)
with the lowest concentration (and lowest proportion having
protective antibody concentrations) being found for antibodies to
serotype 1 in both groups. Serotype 6B, 14 and 23 antibody
concentrations were significantly higher in previously vaccinated
than in control children (Table 1).
Antibody response to booster/delayed primary
vaccination with PCV-7
The proportions of children who achieved antibody concentra-
tions $0.35 mg/mL were high 6–8 weeks after booster/delayed
primary vaccination with PCV-7, ranging from 97–100% for
individual PCV-7 serotypes (Table 2). There were no significant
differences in the proportions with ‘‘protective’’ antibody concen-
trations to polysaccharides in PCV-7 (4, 6B, 9V, 14, 18C, 19F and
23F) between groups at 6–8 weeks or at 16–18 months post-
vaccination, after accounting for multiple significance tests.
However, the geometric mean antibody concentration in the
PCV-9 group was higher than in the control group for serotypes
6B, 9V and 23F at 6–8 weeks but only for serotype 6B at 16–18
months after boosting (Fig. 2 and Table 1).
Fig. 2 shows the kinetics of the antibody response following
booster/delayed primary vaccination with PCV-7. For the PCV-7
serotypes, antibody concentrations increased markedly at 6–8 weeks
after vaccination with PCV-7 (Visit 2) but then fell sharply in both
groups, though remaining higher than pre-PCV-7 levels at 16–18
months post-vaccination. For serotypes 1 and 5 which are in PCV-9
but not PCV-7, GM concentrations at 6–8 weeks were no higher than
pre-boost in the PCV-9 group, but had increased at 16–18 months
post-boost; concentrations in the control group increased over time.
Nasopharyngeal carriage
The proportions of study children who carried pneumococci of
each of the PCV-7 serotypes, and serotypes 1 and 5, present in
Figure 1. A consort diagram indicating number of study participants per study group and visit.
doi:10.1371/journal.pone.0031050.g001
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PCV-9, are shown at different time-points post-vaccination for the
two study groups in Table 3. The frequency of nasopharyngeal
carriage of each individual serotype was too low to allow
meaningful individual comparisons, and no child carried types 1
or 5 at any time point post-vaccination. Thus, further comparisons
were done for carriage of any PCV-9 serotype, PCV-9-related
types, and non-PCV-9 serotypes between the groups. No
significant differences were found in the proportions of nasopha-
ryngeal carriers in these categories between the two groups at any
time point. The tendency for children in the vaccinated group to
carry more non-vaccine serotypes (39%) than children in the
control group (28%) remained at 6–8 weeks post-vaccination but
not at 5 months post-PCV-7 or later.
Discussion
A substantial proportion of the children in the Gambian
pneumococcal vaccine trial had antibody concentrations consid-
ered to be protective against invasive pneumococcal diseases for
most of the serotypes investigated at the age of 3–5 years,
regardless of whether or not they had received PCV-9, although
proportions were a little higher overall for children who had
previously been vaccinated with PCV-9 and substantially higher
for some serotypes. The relatively high concentrations of anti-
pneumococcal antibodies observed in our study population are
similar to those demonstrated previously in PCV vaccinated
Gambian children [11,20,21]. The significant differences in
Table 1. Geometric means (95% CI) of IgG antibody concentrations (mg/mL) before and after boosting with PCV-7 in the group
that previously had placebo (Control) or PCV-9 (Vaccinated).
Before vaccination with PCV-7 6–8 weeks post-PCV-7 (visit 2) 16–18 months post-PCV-7 (visit 4)
Serotype Control Vaccinated Control Vaccinated Control Vaccinated
In PCV-9 only
1 0.095 (0.057–0.157) 0.130 (0.082–0.205) 0.206 (0.126–0.335) 0.094 (0.054–0.164) 0.183 (0.099–0.338) 0.294 (0.165–0.523)
5 0.510 (0.328–0.793) 0.502 (0.331–0.762) 0.759 (0.523–1.101) 0.573 (0.384–0.855) 1.045 (0.670–1.632) 1.862 (1.401–2.474)
In PCV-7
and PCV-9
4 0.398 (0.263–0.603) 0.352 (0.227–0.547) 9.009 (7.808–10.394) 7.864 (6.709–9.218) 1.125 (0.810–1.561) 1.301 (1.056–1.602)
6B 0.092 (0.056–0.150) 1.485* (1.09–2.02) 6.688 (5.112–8.750) 38.181* (29.136–50.034) 2.881 (2.199–3.773) 6.814 (5.662–8.201)
9V 0.626 (0.454–0.857) 0.647 (0.479–0.875) 5.514 (4.700–6.468) 7.912* (6.803–9.202) 2.006 (1.701–2.366) 1.733 (1.514–1.984)
14 0.320 (0.188–0.547) 1.127* (0.720–1.766) 16.553 (12.039–22.760) 20.097 (16.680–24.213) 3.584 (2.489–5.161) 3.348 (2.461–4.556)
18C 0.173 (0.112–0.267) 0.213 (0.143–0.318) 4.935 (3.958–6.154) 5.520 (4.803–6.345) 1.136 (0.869–1.486) 1.172 (1.009–1.362)
19F 2.168 (1.76–2.68) 2.968 (2.55–3.46) 8.347 (6.793–10.257) 8.074 (6.924–9.415) 5.195 (4.060–6.647) 5.256 (4.424–6.245)
23F 0.094 (0.061–0.146) 0.305* (0.209–0.445) 4.376 (3.452–5.549) 8.243* (6.669–10.188) 0.911 (0.650–1.277) 1.297 (0.981–1.715)
*The GMs of antibodies to these serotypes were significantly higher in the vaccinated group than the controls.
doi:10.1371/journal.pone.0031050.t001
Table 2. Proportions of children aged 3–4 years with antibody concentration $0.35 mg/mL before and after vaccination with PCV-
7.
Baseline (visit 1) 6–8 weeks post-PCV-7 (visit 2) 16–18 months post-PCV-7 (visit 4)
Serotype Vaccinated Control p-value Vaccinated Control p-value Vaccinated Control p-value
In PCV-9 only n(% pos) n(% pos)) n (% pos) n (% pos) n(% pos) n (%pos)
1 135 (47) 141 (52) 0.473 124(54) 130(63) 0.143 96(70) 104(61) 0.127
5 137 (82) 144 (82) 0.906 122(86) 130(89) 0.445 97(98) 102(91) 0.851{
In PCV-7 and PCV-9
4 138 (67) 144 (72) 0.436 128 (100) 135(100) 1.000 102(97) 110(92) 0.099
6B 134 (91) 142 (47) ,0.0001 94(99) 125(97) 0.295 104(100) 112(96) 0.696
9V 137 (84) 143 (80) 0.439 128(100) 136(100) 1.000 102(98) 109(97) 0.706
14 138 (88) 144 (72) 0.023* 129(100) 130(98) 0.157 105(98) 108(97) 0.674
18C 138 (55) 144 (56) 0.935 129(100) 137(99) 0.168 96(95) 111(96) 0.814
19F 138 (99) 144 (96) 0.215 129(100) 137(99) 0.331 106(100) 111(99) 0.327
23F 138 (60) 144 (37) 0.003** 124(99) 134(98) 0.352 98(94) 100(85) 0.946{
*P value = 0.0009 before Holm’s correction for multiple significance tests.
**P value = 0.0001 before Holm’s correction for multiple significance tests.
{P value = 0.037 before Holm’s correction for multiple significance tests.
{P value = 0.043 before Holm’s correction for multiple significance tests.
doi:10.1371/journal.pone.0031050.t002
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Figure 2. Geometric mean of IgG antibody concentrations (mg/mL) before and after vaccination with PCV-7 in the two groups (visit
1 =pre-vaccination).
doi:10.1371/journal.pone.0031050.g002
Table 3. Nasopharyngeal carriage of Streptococcus pneumoniae before and after vaccination with a single dose of PCV-7.
Serotype Baseline (visit 1)
6–8 weeks post-PCV-7
(visit 2)
5 months post-PCV-7
(visit 3)
16–18 months
post-PCV-7 (visit 4)
Vaccinated
(N=137)*
n (%)**
Control
(N=143)
n (%)
P
value
Vaccinated
(N=129)
n (%)
Control
(N=138)
n (%)
P
value
Vaccinated
(N=131)
n (%)
Control
(N=138)
n (%)
P
value
Vaccinated
(N=106)
n (%)
Control
(N=99)
n (%)
P
value
1 0 1 (0.7) 1.00 0 0 NA 0 0 NA 0 0 NA
4 1 (0.7) 2 (1.4) 1.00 0 0 NA 1 (0.8) 0 0.487 0 0 NA
5 0 0 NA 0 0 NA 0 0 NA 0 0 NA
6B 2 (1.5) 7 (5) 0.174 1(0.8) 4(3) 0.372 1 (0.8) 6 (4) 0.121 0 1(1) 0.483
9V 1 (0.7) 0 0.489 1(0.8) 0 0.483 0 0 NA 0 1(1) 0.483
14 3 (2) 4 (3) 1.00 1(0.8) 2(1.5) 1.000 2 (1.5) 1 (0.7) 0.614 0 0 NA
18C 0 0 NA 0 1(0.7) 1.000 0.000 1 (0.7) 1.000 2(2) 0 0.498
19F 8 (6) 3 (2) 0.131 8(6) 4(3) 0.243 5 (4) 3 (2) 0.491 1(1) 0 1.000
23F 3 (2) 7 (5) 0.336 3(2) 4(3) 1.000 4 (3) 3 (2) 0.717 3(3) 0 0.247
All PCV9 types 18 (13) 24 (17) 0.393 14(11) 15(11) 1.000 13 (10) 13 (9) 0.889 6(6) 2(2) 0.282
All PCV9-related types 23 (17) 28 (20) 0.545 13 (10) 21(15) 0.208 16 (12) 14 (10) 0.57 9(8) 12(12) 0.392
All non-PCV9 types 53 (39) 40 (28) 1{ 50(39) 37(27) 1{ 48 (37) 52 (38) 0.86 30(28) 26(26) 0.756
NA=Not applicable.
*Number of children.
**Number of serotypes (some children had multiple serotypes on a single visit: they have been included in all those serotype groups).
{P value = 0.057 before Holm’s correction for multiple significance tests.
{P value = 0.037 before Holm’s correction for multiple significance tests.
doi:10.1371/journal.pone.0031050.t003
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antibody concentrations prior to vaccination with PCV-7 for
serotypes 6B, 14, and 23F between the groups indicate longevity of
some vaccine induced antibodies. This may be a result of boosting
by natural colonization and occult pneumococcal infection [22].
However, it is of concern that antibody concentrations to serotype
1 polysaccharide were the lowest among those measured, as
pneumococci belonging to this serotype are a frequent cause of
IPD in The Gambia and in other developing countries. The high
antibody concentrations in the control group for serotypes 4, 9V,
14 and 19F probably reflect past carriage with these organisms.
High antibody concentrations to serotype 5, which was not
commonly found in carriage studies of infants in the PVT [23] nor
in this follow-up study, may reflect past short-duration carriage
which is less likely to be detected in cross-sectional studies, and/or
past occult or symptomatic invasive infection. Previous studies of
infants and toddlers in The Gambia have found carriage of
serotypes 19F, 6B, 23F and 9V to be the most common among the
vaccine-serotypes [23]. Similar vaccine serotypes were found to be
the most common in another carriage study that cuts across all age
groups including adults prior to national routine PCV-7
vaccination in the Western Region of the Gambia [24]. A high
proportion of children with antibody concentrations of $0.2 mg/
mL 5 years after primary vaccination with PCV-9 was described
for serotypes 4, 6B, 9V, 18C, and 23F among HIV uninfected
South African children [25]; in our study proportions were lower
for serotypes 1, 4, 18C and 23F than for other PCV-9-serotypes.
These data support the existence of differential host and/or
environmental factors influencing the responses to the various
serotypes contained within pneumococcal conjugate vaccines.
A strong response to PCV-7 at the age of 3–5 years was seen in
children in both groups. The proportion of children with antibody
concentrations considered to be protective against invasive
pneumococcal disease more than 3 years after primary immuni-
zation ranged from 55 to 99% in the PCV-9 group and 47 to 96%
in controls, but the booster/delayed primary vaccination increased
this proportion to .90% for all PCV-7 serotypes in both groups
for up to 18 months, except for serotype 23F in controls which had
fallen to 85% at 18 months post-PCV-7. These increases in the
antibody concentration following booster/delayed primary PCV-7
contribute to consideration of whether or not to include a booster
dose in the PCV vaccination schedule in countries where carriage
of pneumococci is common. Such a review of vaccination
schedules would require a study with more frequent assessment
of the kinetics of antibody concentrations to fully assess a potential
anamnestic response among previously vaccinated children. We
have shown recently that in resource-poor settings, administration
of a booster dose of pneumococcal polysaccharide vaccine (PPV-
23) following primary immunization with one or two doses of
PCV-7 diminished the differences in initial antibody responses and
might lower the cost [26]. Further study of optimal pneumococcal
vaccination schedules would be helpful [27,28]. The effect of a
single dose of PCV-7 on antibody concentrations in the control
group also supports the WHO recommendation that when PCV is
first introduced into routine childhood immunization programmes
a single catch-up dose of PCV-7 may be given to previously
unvaccinated children aged 12–24 months and to children aged 2–
5 years who are at high risk [27].
No significant differences were found in the proportions of
children carrying pneumococci between the children who had
received booster/delayed primary vaccination and the control
group at any time point. Following booster or delayed primary
immunization with PCV-7 there was a small decline in the
prevalence of carriage with pneumococci of vaccine serotype as
might have been expected, which was not seen for non-vaccine
serotypes. The initial sample size calculation for this study was
based on the assumption that the overall carriage rate of
pneumococci of vaccine serotype in children in the control group
would be 75%. Because this figure was only 17% there was
minimal power to detect significant differences between groups.
The increase in prevalence of carriage of pneumococci of non-
vaccine type among children who had received PCV-9 in infancy
previously reported [23] persisted to the age of 3–4 years and up to
6 weeks after the booster vaccination, but this difference was
minimal at and after 5 months post-PCV-7 vaccination.
Our study was not designed to assess correlation between
antibody levels and carriage. Another report showed high levels of
functional antibody after post-primary PPV-23 vaccination
without impact on carriage, although there had appeared to be
an effect of the number of doses of conjugate vaccine received on
carriage at age 9 months [29]. An earlier study of primary
conjugate pneumococcal vaccination had found that higher IgG
concentrations led to a decreasing probability of having a new
acquisition of pneumococcal carriage of the corresponding
serotype, and achieved statistical significance for serotypes 14
and 19F [30]. Among adults, a pneumococcal anticapsular IgG
concentration of 5 ug/mL has been shown to correlate with
protection against carriage of serotype 14 [31].
The prevalence of carriage before PCV-7 vaccination was lower
than has been reported previously in other parts of The Gambia
where overall carriage across a community including adults was
72%. It was 97% among children ,1 year old and 93% among
babies of ages ,1 month [24,32]. The lower than expected
carriage of pneumococci before PCV-7 vaccination was surprising
and may be in part related to temporal trends in pneumococcal
carriage but also to the increasing age of the study population.
In conclusion, there were significantly higher antibody concen-
trations to 3 of the 9 serotypes in vaccinated children compared to
controls approximately 3 years after primary vaccination with
PCV-9, and antibody levels in PCV-9 recipients and controls were
increased by PCV-7. Carriage of vaccine serotypes was low in both
groups and we could not assess adequately the effect of PCV-7 on
this endpoint.
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